文献速递胸部肿瘤放疗放疗物理与技术

整合疗前与疗中CT的深度学习模型预测非小细胞肺癌放疗反应

Establishing a Deep Learning Model That Integrates Pretreatment and Midtreatment Computed Tomography to Predict Treatment Response in Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-03-13

该研究回顾性收集3家医院168例非小细胞肺癌患者数据,构建整合疗前与疗中CT的深度学习模型预测放疗反应。整合模型在内外部验证中AUC分别为0.869和0.798,优于仅用疗前CT的0.762和0.687。研究据此为29例预测疗效欠佳者推导个体化剂量提升方案。

要点

  • 整合疗前与疗中CT的模型内外部验证AUC为0.869和0.798。
  • 仅用疗前CT的模型内外部验证AUC为0.762和0.687。
  • 基于模型为29例预测疗效欠佳者推导个体化剂量提升。

核心结论

  • 整合疗前与疗中CT可提升非小细胞肺癌放疗反应的预测性能,并为个体化剂量提升提供有前景的方法。

研究设计与样本

  • 回顾性收集3家医院共168例非小细胞肺癌患者数据用于模型训练与验证。
  • 上海市第一人民医院35例与山西省肿瘤医院93例用于模型训练和内部验证。
  • 临汾市中心医院40例用于外部验证。
  • 提取深度学习、影像组学和临床特征,建立变时间间隔长短期记忆网络进行反应预测。
  • 以受试者工作特征曲线下面积和预测绝对误差评价预测的实体瘤疗效评价标准分类及大体肿瘤体积残留比例。

主要发现

  • 仅用疗前CT的模型内部验证AUC为0.762,外部验证AUC为0.687。
  • 整合疗前与疗中CT的模型内部验证AUC为0.869,外部验证AUC为0.798,预测绝对误差分别为0.137和0.185。
  • 对29例患者进行个体化剂量提升,其原生物等效剂量约为72 Gy,范围71.6 Gy至75 Gy。
  • 29例患者的剂量提升范围为77.7 Gy至120 Gy,其中17例超过100 Gy,8例达到模型预设上限120 Gy。

关键数值与推荐

  • 模型整合疗前与疗中CT预测放疗反应的内外部验证AUC分别为0.869和0.798。
  • 预测绝对误差内外部验证分别为0.137和0.185。
  • 剂量提升按α/β比值为10 Gy计算生物等效剂量。
  • 29例患者原生物等效剂量约72 Gy,范围71.6 Gy至75 Gy。
  • 29例患者剂量提升范围77.7 Gy至120 Gy,17例超过100 Gy,8例达预设上限120 Gy。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with identical stages or similar tumor volumes can vary significantly in their responses to radiation therapy (RT) due to individual characteristics, making personalized RT for non-small cell lung cancer (NSCLC) challenging. This study aimed to develop a deep learning model by integrating pretreatment and midtreatment computed tomography (CT) to predict the treatment response in NSCLC patients. METHODS AND MATERIALS: We retrospectively collected data from 168 NSCLC patients across 3 hospitals. Data from Shanghai General Hospital (SGH, 35 patients) and Shanxi Cancer Hospital (SCH, 93 patients) were used for model training and internal validation, while data from Linfen Central Hospital (LCH, 40 patients) were used for external validation. Deep learning, radiomics, and clinical features were extracted to establish a varying time interval long short-term memory network for response prediction. Furthermore, we derived a model-deduced personalize dose escalation (DE) for patients predicted to have suboptimal gross tumor volume regression. The area under the receiver operating characteristic curve (AUC) and predicted absolute error were used to evaluate the predictive Response Evaluation Criteria in Solid Tumors classification and the proportion of gross tumor volume residual. DE was calculated as the biological equivalent dose using an /α/β ratio of 10 Gy. RESULTS: The model using only pretreatment CT achieved the highest AUC of 0.762 and 0.687 in internal and external validation respectively, whereas the model integrating both pretreatment and midtreatment CT achieved AUC of 0.869 and 0.798, with predicted absolute error of 0.137 and 0.185, respectively. We performed personalized DE for 29 patients. Their original biological equivalent dose was approximately 72 Gy, within the range of 71.6 Gy to 75 Gy. DE ranged from 77.7 to 120 Gy for 29 patients, with 17 patients exceeding 100 Gy and 8 patients reaching the model's preset upper limit of 120 Gy. CONCLUSIONS: Combining pretreatment and midtreatment CT enhances prediction performance for RT response and offers a promising approach for personalized DE in NSCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chen X, Meng F, Zhang P, et al. Establishing a Deep Learning Model That Integrates Pretreatment and Midtreatment Computed Tomography to Predict Treatment Response in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40089073. doi:10.1016/j.ijrobp.2025.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。